Progressive Hemodialysis

Is It The Future?

Carmelo Libetta, Peni Nissani, Antonio Dal Canton

Research output: Contribution to journalArticle

Abstract

Progressive hemodialysis is based on the simple idea of adjusting its dose according to residual renal function (RRF). The progressive, infrequent paradigm is slowly gaining a foothold among nephrologists, despite a lot of skepticism in the scientific world. Given the importance of RRF preservation in conservative therapy, it seems a contradiction to ignore the contribution of RRF when patients initiate hemodialysis (HD), especially when it is routinely considered with peritoneal dialysis. While a three-times-weekly HD regimen is broadly considered the standard starting regimen for new patients, twice-weekly HD has been used in selected patients and is currently a common practice in South-East Asia. Small studies indicate that a once-weekly HD regimen may be a viable starting option as well. Progressive hemodialysis still requires validation, yet it is promising. We share the belief that a randomized clinical trial to investigate progressive hemodialysis is much needed, but we also strongly recommend including a once-weekly HD starting dose as part of any such investigation.

Original languageEnglish
Pages (from-to)179-83
Number of pages5
JournalSeminars in Dialysis
Volume29
Issue number3
DOIs
Publication statusPublished - May 2016

Fingerprint

Renal Dialysis
Kidney
Far East
Peritoneal Dialysis
Randomized Controlled Trials

Keywords

  • Editorial

Cite this

Progressive Hemodialysis : Is It The Future? / Libetta, Carmelo; Nissani, Peni; Dal Canton, Antonio.

In: Seminars in Dialysis, Vol. 29, No. 3, 05.2016, p. 179-83.

Research output: Contribution to journalArticle

Libetta, Carmelo ; Nissani, Peni ; Dal Canton, Antonio. / Progressive Hemodialysis : Is It The Future?. In: Seminars in Dialysis. 2016 ; Vol. 29, No. 3. pp. 179-83.
@article{e287140482ff42f391e93f1dbf479fe5,
title = "Progressive Hemodialysis: Is It The Future?",
abstract = "Progressive hemodialysis is based on the simple idea of adjusting its dose according to residual renal function (RRF). The progressive, infrequent paradigm is slowly gaining a foothold among nephrologists, despite a lot of skepticism in the scientific world. Given the importance of RRF preservation in conservative therapy, it seems a contradiction to ignore the contribution of RRF when patients initiate hemodialysis (HD), especially when it is routinely considered with peritoneal dialysis. While a three-times-weekly HD regimen is broadly considered the standard starting regimen for new patients, twice-weekly HD has been used in selected patients and is currently a common practice in South-East Asia. Small studies indicate that a once-weekly HD regimen may be a viable starting option as well. Progressive hemodialysis still requires validation, yet it is promising. We share the belief that a randomized clinical trial to investigate progressive hemodialysis is much needed, but we also strongly recommend including a once-weekly HD starting dose as part of any such investigation.",
keywords = "Editorial",
author = "Carmelo Libetta and Peni Nissani and {Dal Canton}, Antonio",
note = "{\circledC} 2015 Wiley Periodicals, Inc.",
year = "2016",
month = "5",
doi = "10.1111/sdi.12455",
language = "English",
volume = "29",
pages = "179--83",
journal = "Seminars in Dialysis",
issn = "0894-0959",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Progressive Hemodialysis

T2 - Is It The Future?

AU - Libetta, Carmelo

AU - Nissani, Peni

AU - Dal Canton, Antonio

N1 - © 2015 Wiley Periodicals, Inc.

PY - 2016/5

Y1 - 2016/5

N2 - Progressive hemodialysis is based on the simple idea of adjusting its dose according to residual renal function (RRF). The progressive, infrequent paradigm is slowly gaining a foothold among nephrologists, despite a lot of skepticism in the scientific world. Given the importance of RRF preservation in conservative therapy, it seems a contradiction to ignore the contribution of RRF when patients initiate hemodialysis (HD), especially when it is routinely considered with peritoneal dialysis. While a three-times-weekly HD regimen is broadly considered the standard starting regimen for new patients, twice-weekly HD has been used in selected patients and is currently a common practice in South-East Asia. Small studies indicate that a once-weekly HD regimen may be a viable starting option as well. Progressive hemodialysis still requires validation, yet it is promising. We share the belief that a randomized clinical trial to investigate progressive hemodialysis is much needed, but we also strongly recommend including a once-weekly HD starting dose as part of any such investigation.

AB - Progressive hemodialysis is based on the simple idea of adjusting its dose according to residual renal function (RRF). The progressive, infrequent paradigm is slowly gaining a foothold among nephrologists, despite a lot of skepticism in the scientific world. Given the importance of RRF preservation in conservative therapy, it seems a contradiction to ignore the contribution of RRF when patients initiate hemodialysis (HD), especially when it is routinely considered with peritoneal dialysis. While a three-times-weekly HD regimen is broadly considered the standard starting regimen for new patients, twice-weekly HD has been used in selected patients and is currently a common practice in South-East Asia. Small studies indicate that a once-weekly HD regimen may be a viable starting option as well. Progressive hemodialysis still requires validation, yet it is promising. We share the belief that a randomized clinical trial to investigate progressive hemodialysis is much needed, but we also strongly recommend including a once-weekly HD starting dose as part of any such investigation.

KW - Editorial

U2 - 10.1111/sdi.12455

DO - 10.1111/sdi.12455

M3 - Article

VL - 29

SP - 179

EP - 183

JO - Seminars in Dialysis

JF - Seminars in Dialysis

SN - 0894-0959

IS - 3

ER -